

# UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 27, 2004

Date of Deposit

Signature

EL 964841626 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: DEAV2003/0015 US NP  
INVENTORS: GOERLITZER, et al.  
TITLE: 1,3-SUBSTITUTED CYCLOALKYL  
DERIVATIVES HAVING ACIDIC, MOSTLY  
HETEROCYCLIC GROUPS, PROCESSES FOR THEIR  
PREPARATION AND THEIR USE AS  
PHARMACEUTICALS

## APPLICATION ELEMENTS

1. ☒ \*Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)

2. ☒ Specification  
(preferred arrangement set forth below)
- Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure

Total Pages

91

3. ☐ Drawing(s) (35 U.S.C. 113)

Total Sheets

4. Oath or Declaration

Total Pages

- a. ☒ Newly unexecuted (original or copy)

2

- b. ☐ Copy from a prior application (37 CFR § 1.63(d))

- i. ☐ DELETION OF INVENTOR(S)

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).

5. Power of Attorney

Total Pages

- a. ☐ Newly executed (original or copy)

- b. ☐ Copy from a prior application (37 CFR § 1.63(d))

6. ☐ Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission

(if applicable, all necessary)

- a. ☒ Computer Readable Copy  
b. ☒ Paper Copy (identical to computer copy)  
c. ☒ Statement verifying identity of above copies

☐ If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part

of prior application no: \_\_\_\_\_, filed \_\_\_\_\_,

Examiner \_\_\_\_\_, Group/Art Unit \_\_\_\_\_.

(The cross reference has been/will be inserted on page one of the specification).

☒ This application claims the benefit of U.S. Provisional Application No. 60/487,566, filed July 15, 2003. (The cross reference has been/will be inserted on page one of the specification).

☐ **Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

**ACCOMPANYING APPLICATION PARTS**


7. ☐ Assignment Papers (cover sheet & document(s))  
8. ☐ 37 CFR §3.73(b) Statement (when there is an assignee)  
9. ☐ Verified English Translation Document (if applicable)  
10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations  
11. ☐ Preliminary Amendment  
12. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  
13. ☐ \*Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)  
14. ☒ Certified Copy of Priority Document(s) (DE 103 08 351.0 filed on February 27, 2003)  
15. ☒ Other: Application Data Sheet

**CORRESPONDENCE ADDRESS**

☒ Customer Number or Bar Code Label

**005487**

(Insert Customer No. or Attach bar code label here)



Barbara E. Kurys, Reg. No. 34,650  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2003/0015 US NP

13142  
U.S. PTO

PTO/SB/17 (01-03)

Approved for use through 04/30/2003. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL**  
**for FY 2004**

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$)**950.00****Complete if Known**

|                      |                     |
|----------------------|---------------------|
| Application Number   | Not Yet Known       |
| Filing Date          | February 27, 2004   |
| First Named Inventor | GOERLITZER, et al.  |
| Examiner Name        | Not Yet Known       |
| Group / Art Unit     | Not Yet Known       |
| Attorney Docket No.  | DEAV2003/0015 US NP |

|   |                        |   |  |
|---|------------------------|---|--|
| <b>METHOD OF PAYMENT</b> (check all that apply)   |                        | <b>FEE CALCULATION</b> (continued)                        |  |
| <input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None |                        | <b>3. ADDITIONAL FEES</b>                                 |  |
| <input checked="" type="checkbox"/> Deposit Account   |                        | Large Entity      Small Entity                            |  |
| Deposit Account Number: 18-1982   |                        | Fee Code      Fee (\$)                                    |  |
| Deposit Account Name: Aventis Pharmaceuticals Inc.  |                        | Fee Description   |  |
| The Commissioner is authorized to: (check all that apply)   |                        | Fee Paid  |  |
| <input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments   |                        |   |  |
| <input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application  |                        |   |  |
| <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account   |                        |   |  |
| <b>FEE CALCULATION</b>  |                        |   |  |
| <b>1. BASIC FILING FEE</b>  |                        |   |  |
| Large Entity  | Small Entity           |   |  |
| Fee Code      Fee (\$)  | Fee Code      Fee (\$) | Fee Description   |  |
| 1001 770  | 2001 375               | Utility filing fee  |  |
| 1002 340  | 2002 165               | Design filing Fee   |  |
| 1003 530  | 2003 260               | Plant filing fee  |  |
| 1004 770  | 2004 375               | Reissue filing fee  |  |
| 1005 160  | 2005 80                | Provisional filing fee                                    |  |
| <b>SUBTOTAL (1)</b> (\$) <b>770.00</b>  |                        |   |  |
| <b>2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE</b>  |                        |   |  |
| Total Claims 30 - 20** = 10 x 18 = 180  |                        |   |  |
| Independent 1 - 3** =      x      =   |                        |   |  |
| Claims  |                        |   |  |
| Multiple Dependent      =   |                        |   |  |
| Large Entity  | Small Entity           |   |  |
| Fee Code      Fee (\$)  | Fee Code      Fee (\$) | Fee Description   |  |
| 1202 18   | 2202 9                 | Claims in excess of 20                                    |  |
| 1201 86   | 2201 42                | Independent claims in excess of 3                         |  |
| 1203 290  | 2203 140               | Multiple dependent claim, if not paid                     |  |
| 1204 86   | 2204 42                | **Reissue independent claims over original patent         |  |
| 1205 18   | 2205 9                 | **Reissue claims in excess of 20 and over original patent |  |
| <b>SUBTOTAL (2)</b> (\$) <b>180.00</b>  |                        |   |  |
| **or number previously paid, if greater; For Reissues, see above  |                        |   |  |
| Other fee (specify) _____   |                        |   |  |
| *Reduced by Basic Filing Fee Paid   |                        | <b>SUBTOTAL (3)</b> (\$)                                  |  |

|                     |                                   |                                   |           |
|---------------------|-----------------------------------|-----------------------------------|-----------|
| <b>SUBMITTED BY</b> |                                   | <b>Complete (If applicable)</b>   |           |
| Name (Print/Type)   | Barbara E. Kurys, Reg. No. 34,650 | Registration No. (Attorney/Agent) | 34,650    |
| Telephone           | (908) 231-2965                    | Date                              | 2/27/2004 |
| Signature           | Barbara E. Kurys                  |                                   |           |

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template